Jefferies Assumes Prime Medicine at Buy, Lowers Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Maury Raycroft assumes coverage of Prime Medicine (NASDAQ:PRME) with a Buy rating, while lowering the price target to $15.

May 07, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Maury Raycroft has initiated coverage on Prime Medicine with a Buy rating, but reduced the price target to $15.
The initiation of coverage by a major analyst with a Buy rating typically signals confidence in the company's future performance, potentially leading to increased investor interest and a positive impact on the stock price. However, the reduction in the price target may temper expectations, suggesting a cautious optimism about the stock's valuation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100